ME02806B - Protutijela protiv csf-1r - Google Patents
Protutijela protiv csf-1rInfo
- Publication number
- ME02806B ME02806B MEP-2017-174A MEP17417A ME02806B ME 02806 B ME02806 B ME 02806B ME P17417 A MEP17417 A ME P17417A ME 02806 B ME02806 B ME 02806B
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer
- antibody
- csf
- seq
- intended
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (16)
1. Protutijelo koje se specifično veže na varijantu ljudskog CSF-1R (SEQ ID NO. 15), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
2. Protutijelo koje se specifično veže na ljudski CSF-1R (SEQ ID NO. 16), naznačeno time što sadrži teški lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:9 i laki lanac koji sadrži aminokiselinski slijed sa SEQ ID NO:10.
3. Protutijelo u skladu s patentnim zahtjevima 1-4 ili 2, naznačeno time što sadrži dva teška lanca, od kojih svaki sadrži aminokiselinski slijed sa SEQ ID NO:9. i dva laka lanca, od kojih svaki sadrži aminokiselinski slijed sa SEQ ID NO:10.
4. Farmaceutski pripravak, naznačen time što sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 4, naznačen time što dodatno sadrži dodatno farmaceutsko sredstvo.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi kao medikament.
7. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka.
8. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 7, naznačeno time što je rak leukemija, rak dojke, rak endometrija, rak prostate, rak jajnika, kolorektalni rak, hepatocelularni rak, rak bubrega, multipli mielom ili Hodgkinov limfom.
9. Protutijelo je namijenjeno upotrebi u skladu s patentnim zahtjevom 8, naznačeno time što je rak leukemija, rak dojke, rak endometrija ili rak prostate.
10. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 9, naznačeno time što je rak leukemija, rak dojke ili rak prostate.
11. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevima 6-10, naznačeno time što se protutijelo primijenjuje prije, za vrijeme, uglavnom istodobno s ili nakon početka terapije drugim antikanceroznim liječenjem.
12. Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se navedeno antikancerozno liječenje bira iz skupine koju čine antiangiogenetsko sredstvo, kemoterapijsko sredstvo i antineoplastično sredstvo.
13. Protutijelo, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačeno time što se navedeno antineoplastično sredstvo bira iz skupine koju čine docetaksel, paklitaksel, Herceptin® i doksorubicin.
14. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka kod pacijenta koja se sastoji u mjerenju razine CSF-1 u uzorku uzetom iz pacijenta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, i te u primjeni na pacijentu protutijela u skladu s bilo kojim od patentnih zahtjeva 1-3 ako su razine CSF-1 više od razina CSF-1 nađenih kod kontrolne populacije.
15. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeno time što je namijenjeno upotrebi u liječenju raka kod pacijenta koja se sastoji u mjerenju razine IL-34 u uzorku uzetom iz pacijenta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, te u primjeni na pacijentu protutijela u skladu s bilo kojim od patentnih zahtjeva 1-3 ako su razine IL-34 više od razina IL-34 nađenih kod kontrolne populacije.
16. Postupak određivanja je li subjekt koji ima rak kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R, gdje je navedeno protutijelo protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što se sastoji u: određivanju razine CSF-1 ili IL-34, ili oba, ex vivo ili in vitro u uzorku iz subjekta, gdje se uzorak bira iz skupine koju čine krv, serum, plazma, tumorske stanice i tumorske stanice u cirkulaciji, gdje porast razine CSF-1, ili IL-34, ili oba, u usporedbi s razinom CSF-1, ili IL-34, ili oba, kod pojedinca koji ne boluje od raka, ukazuje da je subjekt kandidat za režim liječenja raka na bazi protutijela protiv CSF-1R.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| EP11713416.3A EP2552966B1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02806B true ME02806B (me) | 2018-01-20 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-174A ME02806B (me) | 2010-04-01 | 2011-03-28 | Protutijela protiv csf-1r |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (me) |
| EP (2) | EP2552966B1 (me) |
| JP (1) | JP5767310B2 (me) |
| KR (1) | KR101439719B1 (me) |
| CN (1) | CN102834414B (me) |
| AR (1) | AR080698A1 (me) |
| AU (1) | AU2011232850B2 (me) |
| BR (1) | BR112012024564A2 (me) |
| CA (1) | CA2795081C (me) |
| CY (1) | CY1119324T1 (me) |
| DK (1) | DK2552966T3 (me) |
| EA (1) | EA021600B1 (me) |
| ES (1) | ES2640909T3 (me) |
| HR (1) | HRP20171153T1 (me) |
| HU (1) | HUE036379T2 (me) |
| IL (1) | IL222222A (me) |
| JO (1) | JO3291B1 (me) |
| LT (1) | LT2552966T (me) |
| ME (1) | ME02806B (me) |
| MX (1) | MX2012011234A (me) |
| NZ (1) | NZ602621A (me) |
| PL (1) | PL2552966T3 (me) |
| PT (1) | PT2552966T (me) |
| RS (1) | RS56219B1 (me) |
| SG (1) | SG183829A1 (me) |
| SI (1) | SI2552966T1 (me) |
| TW (1) | TWI402078B (me) |
| UA (1) | UA111818C2 (me) |
| WO (1) | WO2011123381A1 (me) |
| ZA (1) | ZA201206926B (me) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| US9161968B2 (en) * | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| EP2791174B1 (en) * | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104093740B (zh) * | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| JP6667438B2 (ja) | 2013-12-09 | 2020-03-18 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 老化に関連する状態を処置する方法及び組成物 |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| CN113350501A (zh) | 2014-06-23 | 2021-09-07 | 戊瑞治疗有限公司 | 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AU2015339306B2 (en) | 2014-10-29 | 2021-07-22 | Bristol-Myers Squibb Company | Combination therapy for cancer |
| EA201791421A1 (ru) | 2014-12-22 | 2017-10-31 | Файв Прайм Терапьютикс, Инк. | Антитела против csf1r для лечения pvns |
| BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| JP6851322B2 (ja) | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
| ES2902467T3 (es) | 2015-06-15 | 2022-03-28 | Univ Leland Stanford Junior | TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| RU2018102575A (ru) * | 2015-06-24 | 2019-07-25 | Ф. Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r, предназначенные для применения для индукции лимфоцитоза при лимфомах или лейкозах |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| CN108367070B (zh) | 2015-11-04 | 2022-10-28 | 杜克大学 | 免疫毒素与检查点抑制剂的组合治疗 |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| US20180291107A1 (en) * | 2015-11-24 | 2018-10-11 | Eli Lilly And Company | Combination therapy for cancer |
| MX2018006445A (es) * | 2015-11-25 | 2018-08-01 | Nogra Pharma Ltd | Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. |
| ES2975517T3 (es) | 2016-04-28 | 2024-07-08 | Alkahest Inc | Fracciones de plasma como terapia para el cáncer de timo |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| JP7138094B2 (ja) | 2016-08-25 | 2022-09-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与 |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| JP7304287B2 (ja) * | 2016-12-22 | 2023-07-06 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| JP2020517256A (ja) | 2017-04-19 | 2020-06-18 | エルスター セラピューティクス， インコーポレイテッド | 多重特異性分子およびその使用 |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| CN117899111A (zh) | 2017-04-26 | 2024-04-19 | 万能溶剂有限公司 | 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案 |
| EP3624848A1 (en) | 2017-05-19 | 2020-03-25 | Syndax Pharmaceuticals, Inc. | Combination therapies |
| TWI817952B (zh) | 2017-08-25 | 2023-10-11 | 美商戊瑞治療有限公司 | Ｂ７－ｈ４抗體及其使用方法 |
| CA3073531A1 (en) | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| EP3720881A1 (en) | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| GB201803226D0 (en) | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| KR102824112B1 (ko) | 2018-03-28 | 2025-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법 |
| MX2020012567A (es) * | 2018-05-23 | 2021-01-29 | Beigene Ltd | Anticuerpos anti-ox40 y metodos de uso. |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
| CN113164777B (zh) | 2018-09-27 | 2024-12-13 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
| UA128648C2 (uk) | 2018-10-26 | 2024-09-18 | Алкахест, Інк. | Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення |
| TWI733274B (zh) | 2018-12-13 | 2021-07-11 | 財團法人生物技術開發中心 | 抗人類csf-1r抗體及其用途 |
| ES2984122T3 (es) * | 2019-03-05 | 2024-10-29 | Inserm Institut National De La Santeet De La Rech Medicale | Biomarcadores para carcinoma de células renales |
| CN113939539B (zh) * | 2019-05-15 | 2024-06-04 | 博奥信生物技术（南京）有限公司 | 结合csf-1r的抗体及其用途 |
| JP2022532837A (ja) * | 2019-05-24 | 2022-07-20 | エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド | 抗ｃｓｆ１ｒ抗体、ｉｌ１０融合タンパク質、及びそれらの使用 |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| CN114430747B (zh) | 2019-09-26 | 2025-02-25 | 豪夫迈·罗氏有限公司 | 抗csf-1r抗体 |
| AU2020366222B2 (en) * | 2019-10-17 | 2024-10-10 | National Health Research Institutes | Use of succinate as biomarker in diagnosis and treatment of cancers |
| EP4051321A4 (en) | 2019-10-30 | 2023-11-22 | Duke University | IMMUNOTHERAPY WITH COMBINATION THERAPY INCLUDING AN IMMUNOTOXIN |
| CA3164126A1 (en) | 2019-12-09 | 2021-06-17 | Syndax Pharmaceuticals, Inc. | Antibodies for the treatment of chronic graft versus host disease |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| TW202446418A (zh) | 2023-05-17 | 2024-12-01 | 美商錫達斯醫藥股份有限公司 | 使用抗群落刺激因子１受體抗體治療慢性移植物抗宿主病相關閉塞性細支氣管炎症候群之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| CA1341411C (en) | 1988-04-16 | 2002-12-17 | Lutz Riechmann | Method for producing fv fragments in eukaryotic cells |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| CN1787837A (zh) | 2002-11-15 | 2006-06-14 | 希龙公司 | 防止和治疗癌转移以及与癌转移相关的骨质损失的方法 |
| LT2620450T (lt) | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| RS56743B1 (sr) * | 2007-08-21 | 2018-03-30 | Amgen Inc | Humani c-fms antigen vezujući proteini |
| CN101970496B (zh) | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171153T1 (hr) | Protutijela protiv csf-1r | |
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| JP2013529183A5 (me) | ||
| Yamamoto et al. | Latest advances in extracellular vesicles: from bench to bedside | |
| Zhang et al. | Near-infrared light irradiation induced mild hyperthermia enhances glutathione depletion and DNA interstrand cross-link formation for efficient chemotherapy | |
| Wang et al. | Nanomaterials for cancer precision medicine | |
| JP2020182492A5 (me) | ||
| Kinoh et al. | Nanomedicines eradicating cancer stem-like cells in vivo by pH-triggered intracellular cooperative action of loaded drugs | |
| Guion-Dusserre et al. | FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2017514143A5 (me) | ||
| JP2019534034A5 (me) | ||
| JP2021528400A5 (me) | ||
| JP2020508317A5 (me) | ||
| Damia et al. | The pharmacological point of view of resistance to therapy in tumors | |
| JP2014530215A5 (me) | ||
| FI4241849T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2013511288A5 (me) | ||
| JP2012019790A5 (me) | ||
| JP2007504280A5 (me) | ||
| RU2014138420A (ru) | Антитела против sez6 и способы их применения | |
| RU2015100231A (ru) | Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения | |
| Zhang et al. | A multifunctional Fe-EGCG@ RSL3 nanomedicine synergizes ferroptosis induction and tumor microenvironment remodeling for enhanced bladder cancer immunotherapy | |
| RU2013138177A (ru) | Антитела, действующие селективно на клетки с повышенной плотностью мишени рецептор эпидермального фактора роста (egfr) | |
| JP2008508858A5 (me) |